The chemical substance known as (exo,exo)-3-(4-Chlorophenyl)-8-methyl-2-[3-(4-methylphenyl)isoxazol-5-yl]-8-azabicyclo[3.2.1]octane hydrochloride, with the CAS number 204069-50-1, is a bicyclic compound characterized by its complex structure that includes a bicyclo[3.2.1]octane framework. This compound features multiple functional groups, including a chlorophenyl moiety and an isoxazole ring, which contribute to its potential biological activity. The presence of the hydrochloride salt form indicates that it is likely soluble in water, enhancing its bioavailability for pharmacological applications. The specific stereochemistry (exo configuration) suggests that the spatial arrangement of atoms may influence its interaction with biological targets, potentially affecting its efficacy and safety profile. Such compounds are often investigated for their therapeutic potential, particularly in the fields of neuroscience and pharmacology, due to their ability to interact with neurotransmitter systems. However, detailed studies on its pharmacodynamics, pharmacokinetics, and toxicity would be necessary to fully understand its characteristics and applications.

(exo,exo)-3-(4-Chlorophenyl)-8-methyl-2-[3-(4-methylphenyl)isoxazol-5-yl]-8-azabicyclo[3.2.1]octane hydrochloride

Applications RTI-336 is a a phenyltropane cocaine analog that acts selective dopamine reuptake inhibitor (1,2,3). RTI-336 binds to the dopamine transporter with around 20 times the affinity of cocaine but produces relatively mild stimulant effects. RTI-336 is a potential candidate for pharmacotherapy for treating cocaine addiction.
References (1) Carroll, F.I. et al.: AAPS J., 8, E196 (2006) (2) Czoty, P.W. et al.: Pharmacol. Biochem. Behav., 96, 274 (2010) (3) Carroll, F.I. et al.: Eur. J. Pharmacol., 553, 149 (2006)


RTI-336

RTI 336 is used as a chronic brain dopamine transporter (DAT) inhibitor.

RTI 336

RTI-336 is a drug that acts as a potent, nonselective dopamine agonist at the D2 receptor. It binds to and activates dopamine receptors in the brain, which are critical for the regulation of reward, motor control, cognition, and emotion. RTI-336 is being investigated in clinical trials for its ability to promote neuronal function and restore psychostimulant responsiveness in humans. The drug also has binding affinity for 5-HT2A receptors with an EC50 value of 0.3 nM. RTI-336 is an analog of lysergic acid diethylamide (LSD), but was designed not to cross the blood-brain barrier and produce hallucinogenic effects.

CAS 204069-50-1: (exo,exo)-3-(4-Chlorophenyl)-8-methyl-2-[3-(4-methylphenyl)isoxazol-5-yl]-8-azabicyclo[3.2.1]octane hydrochloride

RTI-336

Ref: TR-R701250

RTI 336

Ref: TM-T26145

RTI-336

Ref: 3D-EIA06950